SCHEMBL2816218

SCHEMBL2816218

CNc1nc2ccccc2n2c(-c3cccc(Cl)c3)cnc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 7/20 0.47
CHUK O15111 4/20 0.47
HTR2C P28335 1/20 0.44
MAP4K4 O95819 1/20 0.42
TOP2A P11388 1/20 0.41
GAA P10253 1/20 0.40
BRD4 O60885 1/20 0.39
KDM4E B2RXH2 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
IDO1 P14902 1/20 0.39
BACE1 P56817 1/20 0.38
DYRK3 O43781 1/20 0.38
CCNT1 O60563 1/20 0.38
CCNA2 P20248 1/20 0.38
CDK2 P24941 1/20 0.38
CDK9 P50750 1/20 0.38
CDK5 Q00535 1/20 0.38
DYRK1A Q13627 1/20 0.38
CDK5R1 Q15078 1/20 0.38
DYRK2 Q92630 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2816389 0.87 HTR2C (0.47) IKBKBCHUKHTR2CTOP2AKDM4E
SCHEMBL2816677 0.86 HTR2C (0.51) IKBKBCHUKHTR2CTOP2AKDM4E
SCHEMBL2815160 0.86 IKBKB (0.47) IKBKBCHUKHTR2CTOP2AKDM4E
SCHEMBL2816959 0.86 IKBKB (0.47) IKBKBCHUKHTR2CMAP4K4TOP2A
SCHEMBL2815174 0.86 IKBKB (0.48) IKBKBCHUKHTR2CTOP2AKDM4E
SCHEMBL2817655 0.84 ALDH1A1 (0.51) IKBKBCHUKHTR2CTOP2AKDM4E
SCHEMBL30136943 0.84 IKBKB (0.47) IKBKBCHUKHTR2CTOP2AGAA
SCHEMBL2817762 0.84 IKBKB (0.47) IKBKBCHUKHTR2CTOP2AGAA
SCHEMBL2816322 0.84 IKBKB (0.50) IKBKBCHUKBRD4SMN1; SMN2CDK2
SCHEMBL2837045 0.83 IKBKB (0.44) IKBKBCHUKHTR2CTOP2ADYRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2205602-B1 IMIDAZO[1,2-A]QUINOXALINES AND DERIVATIVES THEREOF FOR TREATING CANCERS UNIV MONTPELLIER (FR) 2018-09-26 EP claimed
US-8378098-B2 Imidazol[1,2-α]quinoxalines and derivatives for the treatment of cancers UNIVERSITE DE MONTPELLIER I (FR) 2013-02-19 US claimed
US-20100249142-A1 IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS UNIVERSITE DE MONTPELLIER I 2010-09-30 US claimed
EP-2205602-B1 IMIDAZO[1,2-A]QUINOXALINES AND DERIVATIVES THEREOF FOR TREATING CANCERS UNIV MONTPELLIER (FR) 2018-09-26 EP disclosed
US-8378098-B2 Imidazol[1,2-α]quinoxalines and derivatives for the treatment of cancers UNIVERSITE DE MONTPELLIER I (FR) 2013-02-19 US disclosed
US-20100249142-A1 IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS UNIVERSITE DE MONTPELLIER I 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249142-A1 IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS IDH3A, NRAS, KRAS IKBKB 855/4885CHUK 409/4885HTR2C 1292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.